



# Clinical Outcomes of Adjunctive Coronary Endarterectomy in Patients with Diffuse Coronary Artery Disease: A Pilot Study

Seyed Amir Mohamad Tadayoni <sup>1</sup>, Kamran Ghods <sup>2,\*</sup>, Mohammad Forozeshfard <sup>3</sup>, Majid Mirmohammadkhani <sup>2</sup>

<sup>1</sup> Clinical Research Development Center, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran

<sup>2</sup> Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran

<sup>3</sup> Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran

\*Corresponding Author: Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran. Email: kamran1230@yahoo.com

Received: 28 July, 2025; Revised: 5 October, 2025; Accepted: 7 October, 2025

## Abstract

**Background:** Cardiovascular diseases (CVDs), particularly coronary artery disease (CAD), remain a leading cause of global mortality. While coronary artery bypass grafting (CABG) is a standard treatment, patients with diffuse CAD often require adjunctive techniques to achieve complete revascularization.

**Objectives:** Coronary endarterectomy (CE) has emerged as a valuable adjunct to CABG, aiming to improve blood flow in severely diseased arteries. This study aimed to evaluate the clinical outcomes, changes in blood biomarkers, and postoperative complications in patients undergoing adjunctive CE with CABG.

**Methods:** This retrospective cohort study included 50 patients who underwent CE with CABG between 2012 and 2021. We extracted data on demographics, comorbidities, pre- and postoperative biomarkers, ejection fraction (EF), length of ICU stay, number of grafts, endarterectomized vessel, and postoperative outcomes from medical records. Data were analyzed using descriptive statistics, chi-square tests, independent samples *t*-tests, and Mann-Whitney U tests. Statistical significance was set at  $P < 0.05$ .

**Results:** The mean  $\pm$  SD age of patients was  $63.96 \pm 9.35$  years, with 66% being male. Hypertension (HTN) was the most prevalent comorbidity (66%). The mean  $\pm$  SD hospital stay was  $147.12 \pm 51.51$  hours. A significant decrease in mean EF was observed postoperatively ( $48\% \pm 8.77$  to  $44\% \pm 9.28$ ,  $P = 0.002$ ). Postoperatively, significant increases were noted in white blood cell (WBC) counts, blood urea nitrogen (BUN), creatinine, prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR; all  $P < 0.001$ , except creatinine  $P = 0.002$ ), while hemoglobin (Hb) levels significantly decreased ( $P < 0.001$ ). The majority of patients (46%) received four grafts, and the left anterior descending (LAD) artery was the most common site for endarterectomy (44%). The in-hospital mortality rate was 2%. Acute kidney injury (AKI) was the most frequent complication (38%), followed by dyspnea (28%) and pulmonary edema (20%).

**Conclusions:** Adjunctive CE was associated with a low in-hospital mortality rate and an acceptable complication profile, representing a viable surgical strategy for patients with diffuse CAD, particularly when complete revascularization is challenging. Further large-scale, multi-center prospective studies with long-term follow-up are warranted to validate these findings and explore the influence of specific patient characteristics on long-term outcomes.

**Keywords:** Endarterectomy, CABG, Coronary Artery Disease, Revascularization

## 1. Background

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, accounting for over a third of deaths in developed countries and approximately 50% in

Iran (1-3). Among CVDs, coronary artery disease (CAD) is a prevalent condition and a major contributor to global mortality (4). Despite medical advancements, the World Health Organization (WHO) reported that CAD prevalence has not declined, with annual deaths

estimated to have reached 25 million by 2020 (5). In Iran, societal changes such as industrialization have made CAD a primary cause of death and a common non-communicable disease (6).

Timely diagnosis and effective treatment are crucial for reducing CAD-related mortality and complications (7). Coronary angiography remains the gold standard for diagnosing arterial stenosis, often facilitating simultaneous therapeutic interventions (8, 9). For severe blockages, two main interventional approaches are employed: Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (angioplasty). While angioplasty is less invasive, CABG is frequently necessary, particularly for patients with diffuse lesions, and remains a highly effective treatment (10, 11).

To enhance revascularization in patients with diffuse CAD, where CABG alone may yield suboptimal results, coronary endarterectomy (CE) has emerged as a valuable adjunctive technique (12-14). The CE, initially used to create suitable distal anastomosis sites, improves blood flow and is particularly beneficial in off-pump CABG for diffuse disease (15-18). Studies have shown promising outcomes, with some reporting high survival rates and no major adverse events after left anterior descending (LAD) endarterectomy via an off-pump method (19). Furthermore, off-pump endarterectomy is considered safe, feasible, and associated with better long-term graft patency compared to on-pump methods (20).

However, the definitive role of CE as an adjunct to CABG remains a subject of debate. While some studies suggest that CABG with CE is associated with lower mortality rates compared to CABG alone (12, 18, 21-24), others have indicated potentially higher mortality, though this may be influenced by underlying comorbidities (25). These conflicting findings are often attributed to varying patient population complexity, differences in surgical techniques, and the retrospective nature of many studies, which can introduce selection bias. Given that medical therapy is often less effective for severe coronary stenosis, surgical intervention, particularly with the potential benefits of CE, becomes critical. Given the increasing use of CE and the conflicting evidence regarding its outcomes, a comprehensive examination of its effects on patients is essential.

## 2. Objectives

In this retrospective study, we aimed to determine the safety and short-term clinical outcomes of adjunctive CE in patients with diffuse CAD who

underwent CABG at Kosar Hospital, Semnan, from 2012 to 2021.

## 3. Methods

### 3.1. Study Design and Participants

This retrospective cohort study included all consecutive patients who underwent adjunctive CE with CABG at Kosar Hospital, Semnan, Iran, between March 2012 and March 2021 (Iranian calendar years 1391 - 1399). A census approach was adopted, including all eligible patients within the specified timeframe, thus negating the need for a formal sample size calculation.

### 3.2. Criteria

#### 3.2.1. Inclusion Criteria

Patients who underwent CE as an adjunct to CABG were included.

#### 3.2.2. Exclusion Criteria

Patients were excluded if their medical records were incomplete or if essential data points for the analysis were missing. Patients who underwent concomitant cardiac procedures (e.g., valve surgery) were excluded to ensure a homogeneous cohort focused on the outcomes of CABG with adjunctive CE.

### 3.3. Data Collection

Patient medical records were comprehensively reviewed, and data were extracted into a pre-designed checklist. In cases of missing information, attempts were made to contact patients by phone to complete the data where possible. The collected information included: Demographic data (age, gender), comorbidities, pre- and post-operative blood biomarker levels, pre- and post-operative ejection fraction (EF), clinical course details (length of stay in the intensive care unit, number of grafts, involved coronary vessels), and postoperative outcomes (complications, in-hospital mortality). Postoperative complications were documented from patient records.

Acute kidney injury (AKI) was defined according to the KDIGO criteria, which includes any of the following: An increase in serum creatinine by  $\geq 0.3$  mg/dL within 48 hours; an increase in serum creatinine to  $\geq 1.5$  times baseline within the prior 7 days; or a urine volume of  $< 0.5$  mL/kg/h for 6 hours [Goyal, 2025 #69]. Dyspnea was documented based on new or worsening shortness of breath requiring increased respiratory support.

Pulmonary edema was defined as clinical and radiological evidence of fluid accumulation in the lungs requiring diuretic therapy or increased respiratory support.

A limitation encountered was the absence of some post-operative blood biomarker measurements in patient records. For analysis, missing data points were not imputed; instead, comparisons were restricted to patients with complete pre- and post-operative data for each specific biomarker.

### 3.4. Data Analysis

All statistical analyses were performed using SPSS software (version 22). Descriptive statistics were reported as frequencies and percentages for categorical variables and mean  $\pm$  SD for continuous variables. Comparisons of pre- and post-operative measurements were performed using paired *t*-tests or their non-parametric equivalents (e.g., Wilcoxon signed-rank test), based on data distribution. A *P*-value  $< 0.05$  was considered statistically significant.

### 3.5. Ethical Considerations

The study protocol received approval from the ethics committee of Semnan University of Medical Sciences (ID: [IR.SEMUMS.REC.1400.144](#)). Patient confidentiality was strictly maintained throughout the study.

## 4. Results

This study included 50 patients who underwent coronary artery endarterectomy between 2012 and 2021. The mean  $\pm$  SD age was  $63.96 \pm 9.35$  years (range: 40 to 81 years), and 33 patients (66%) were male. The mean  $\pm$  SD length of hospital stay was  $147.12 \pm 51.51$  hours (range: 48 to 336 hours). The mean  $\pm$  SD EF significantly decreased from  $48\% \pm 8.77$  preoperatively to  $44\% \pm 9.28$  postoperatively ( $P = 0.002$ ). Among the patients, 28 had diabetes, 33 had hypertension (HTN), 12 had hyperlipidemia, and 15 had a history of ischemic heart disease, with some patients presenting with more than one comorbidity.

As shown in [Table 1](#), significant changes were observed in several hematological and biochemical markers post-surgery. White blood cell (WBC) counts, blood urea nitrogen (BUN), creatinine levels, prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) all increased significantly postoperatively ( $P < 0.001$  for WBC, BUN, PT, PTT, INR;  $P = 0.002$  for creatinine). Conversely, hemoglobin (Hb) levels significantly

decreased ( $P < 0.001$ ). No significant changes were observed in platelet counts or sodium, potassium, or calcium levels.

The majority of patients (46%) received four grafts, followed by three grafts (26%). As presented in [Table 2](#), the LAD artery was the most common site for endarterectomy (44% of cases), followed by the right coronary artery (RCA, 40%).

[Table 3](#) summarizes the frequency of postoperative complications. The AKI was the most frequent complication (38%), followed by dyspnea (28%) and pulmonary edema (20%). The in-hospital mortality rate was 2%. Complications such as arrhythmia, re-intubation, tracheostomy, cerebrovascular accident (CVA), and the need for dialysis were not observed in this cohort.

## 5. Discussion

This retrospective study analyzed the clinical outcomes of 50 patients who underwent CE as an adjunct to CABG at Kosar Hospital, Semnan, between 2012 and 2021. During this period, CE was performed in 3.84% (50 out of approximately 1300) of all CABG surgeries at our center. This incidence is lower than some reports, such as 11% by Livesay ([26](#)), potentially reflecting variations in surgical practices, patient selection, or the regional prevalence of diffuse CAD.

Our patient cohort frequently presented with HTN, affecting 66% of individuals. This is consistent with other studies by Sabzi et al. ([27](#)), Balaj et al. ([28](#)), and Alreshidan et al. ([12](#)), underscoring HTN as a common comorbidity in patients requiring coronary revascularization. Furthermore, the mean number of grafts used was 3.02, aligning with reports by Sabzi et al. (3.07) ([27](#)) and Ranjan et al. (3.3) ([29](#)). This suggests appropriate surgical decisions regarding the extent of revascularization for these complex cases. The LAD artery was the most frequently endarterectomized vessel (44%), which is consistent with Ranjan et al.'s findings ([29](#)), though Sabzi et al. reported a higher rate in the RCA ([27](#)).

We observed several expected physiological responses to cardiac surgery, including significant increases in WBC, BUN, creatinine, PT, PTT, and INR, alongside a significant decrease in Hb. These changes are largely attributable to the systemic inflammatory response, potential renal dysfunction, anticoagulation, and intraoperative blood loss. A notable finding was the significant decrease in EF post-operation (48% to 44%,  $P = 0.002$ ). While a transient EF reduction is common post-cardiac surgery due to myocardial stunning, the

**Table 1.** Comparison of Mean Hematology and Biochemical Markers Before and After Surgery<sup>a</sup>

Markers	Before Surgery	After Surgery	P-Value <sup>b</sup>
WBC ( $\times 1000/\text{mL}$ )	8.58 $\pm$ 3.26	12.10 $\pm$ 3.15	< 0.001
Hb (gr/dL)	12.59 $\pm$ 1.94	9.81 $\pm$ 1.39	< 0.001
Platelets ( $\times 1000/\text{mL}$ )	243 $\pm$ 99.4	213 $\pm$ 100.0	0.07
BUN (mg/dL)	19.4 $\pm$ 3.32	24.38 $\pm$ 8.64	< 0.001
Creatinine (mg/dL)	1.01 $\pm$ 0.16	1.13 $\pm$ 0.24	0.002
Sodium (mg/dL)	139.44 $\pm$ 3.24	140.21 $\pm$ 2.89	0.138
Potassium (mg/dL)	4.33 $\pm$ 0.53	4.43 $\pm$ 0.46	0.356
Calcium (mg/dL)	8.7 $\pm$ 0.59	8.66 $\pm$ 0.33	0.376
PT (s)	13.53 $\pm$ 0.80	18.95 $\pm$ 5.5	< 0.001
PTT (s)	35.0 $\pm$ 8.30	45.33 $\pm$ 18.07	< 0.001
INR	1.07 $\pm$ 0.1	2.03 $\pm$ 1.12	< 0.001

Abbreviations: WBC, white blood cell; Hb, hemoglobin; BUN, blood urea nitrogen; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio.

<sup>a</sup> Values are expressed as mean  $\pm$  SD.

<sup>b</sup> Paired *t*-test.

**Table 2.** Frequency and Percentage of Endarterectomy Vessels

Vessel Site	No. (%)
RCA	20 (40)
PDA	14 (28)
PLV	10 (20)
D1	3 (6)
D2	3 (6)
LAD	22 (44)
LCX	1 (2)
OM	3 (6)

Abbreviations: RCA, right coronary artery; PDA, posterior descending artery; PLV, posterior left ventricular branches; D, diagonal branches; LAD, left anterior descending; LCX, left circumflex artery; OM, obtuse marginal.

statistical significance warrants further investigation into its long-term clinical implications and resolution.

The in-hospital mortality rate of 2% in our study is encouraging. Although a direct, unadjusted comparison to the general CABG population is scientifically inappropriate due to the higher-risk profile of CE patients, this low rate suggests that CE can be performed with acceptable short-term outcomes. Our finding is comparable to similar studies, such as the 1.9% reported by Ranjan et al. (29), and is notably lower than the 4.3% reported by Livesay (26). This supports the notion that with careful patient selection, adjunctive CE is a reliable procedure for managing diffuse CAD.

The mean length of hospital stay was 147.12  $\pm$  51.51 hours. This duration appears longer than some reports (e.g., Ranjan et al.'s 36.6  $\pm$  6.7 hours ICU stay) (29), primarily because, at our center, patients are directly

discharged from the open-heart ICU. Thus, our reported "ICU stay" effectively represents the total "hospital stay".

The incidence of atrial fibrillation (AF) in our cohort was 4%, considerably lower than rates reported by GÜVenÇ et al. (37%) (30) and Ranjan et al. (15%) (29). This discrepancy could be influenced by variations in patient characteristics, surgical techniques, or postoperative protocols. The incidence of pleural effusion was 20%, which is lower than the 40% reported by Rossolatos et al. (31) but falls within the wide range (3.1% to 63%) reported in the literature (32-35).

Our most frequent complication was AKI at 38%. This high rate, defined by KDIGO criteria, highlights the vulnerability of this complex patient population to renal impairment post-surgery, likely exacerbated by baseline comorbidities. Dyspnea (28%) was the second most frequent complication. Overall, our findings suggest that adjunctive CE is associated with a low in-

**Table 3.** Frequency of Postoperative Complications in Endarterectomy Patients

Vessel Site	No. (%)
Hemorrhage	2 (4)
Dyspnea	14 (28)
Arrhythmia	0 (0)
Pulmonary edema	10 (20)
Renal impairment	19 (38)
Gastrointestinal symptoms	3 (6)
Need for balloon pump	4 (8)
Re-intubation	0 (0)
Tracheostomy	0 (0)
CVA	0 (0)
Need for dialysis	0 (0)
AF	2 (4)
RBBB	6 (12)
Tamponade	6 (12)
Chest pain	8 (16)
Ventricular fibrillation	1 (2)
Mortality	1 (2)

Abbreviations: CVA, cerebrovascular accident; AF, atrial fibrillation.

hospital mortality rate. Although the procedure carries expected risks for complex cardiac surgery, such as renal impairment and pulmonary edema, the outcomes support its viability as a treatment option for patients with diffuse CAD.

### 5.1. Conclusions

In our cohort, CE as an adjunct to CABG was associated with a low in-hospital mortality rate and a predictable profile of complications. While transient changes in biomarkers and events like bleeding occurred, these are often manageable consequences of complex cardiac surgery and necessary anticoagulation. Therefore, our findings support adjunctive CE as a viable and effective treatment strategy for patients with diffuse CAD. Based on these outcomes, CE can be considered a safe and effective method for treating CAD patients, particularly those with diffuse lesions.

To address the limitations of this study, we recommend larger, multi-center prospective studies with long-term follow-up. These studies should aim to further investigate the influence of comorbidities, the specific artery involved, and different surgical techniques on postoperative complications and long-term clinical outcomes.

### 5.2. Limitations

This study has several limitations inherent to its design. First, its retrospective nature may have led to incomplete data capture. Second, the small sample size ( $n = 50$ ) limits the generalizability of our findings and the statistical power to detect smaller differences or rare complications. Furthermore, the single-center design may introduce selection bias related to our institution's specific practices and patient demographics. Finally, the lack of long-term follow-up data is a major limitation, preventing insights into the durability of revascularization and long-term survival. Future multi-center, prospective studies with larger cohorts and long-term follow-up are necessary to validate these findings and provide a more comprehensive understanding of this procedure's outcomes.

### 5.3. Implications for Health Policy, Practice, Research, and Medical Education

This study, conducted at Semnan's sole cardiac surgery center, offers crucial insights into the outcomes of CE combined with CABG. With a low in-hospital mortality rate (2%) and an acceptable complication profile, our findings affirm CE as a safe and effective revascularization strategy for diffuse CAD. This reinforces its continued use in clinical practice, particularly in cases where complete revascularization is otherwise challenging.

The observed longer hospital stays, directly linked to our center's practice of discharging patients from the

ICU, highlight a need for tailored postoperative care pathways and efficient resource allocation in similar healthcare settings. This research underscores the importance of regional data in shaping health policy and medical education. It advocates for the continued provision of resources for CE services and suggests incorporating our real-world findings into medical training to better prepare professionals for managing these complex patients.

Furthermore, this study paves the way for future prospective, multi-center trials with larger cohorts to validate these outcomes, investigate long-term graft patency, and explore the impact of specific comorbidities, ultimately refining our understanding and improving patient care in cardiac surgery.

## Footnotes

**Authors' Contribution:** Conceptualization: K. G. and M. F.; Data curation: S. A. M. T.; Formal analysis: M. M.; Funding acquisition: K. G.; Investigation: M. F.; Methodology: M. M.; Project administration: K. G.; Resources: M. F. and S. A. M. T.; Supervision: K. G.; Validation: M. F.; Visualization: K. G. and M. F.; Writing-original draft: M. F. and S. A. M. T.; Writing-review and editing: K. G. and M. F.

**Conflict of Interests Statement:** We declare that one of our authors (Majid Mirmohammadkhani) is of the editorial board. The journal confirmed that the author with CoI was excluded from all review processes.

**Data Availability:** The dataset generated and analyzed during this study is available from the corresponding author upon reasonable request, either during the submission process or after publication.

**Ethical Approval:** The research was conducted in accordance with the tenets of the Declaration of Helsinki. The Ethics Committee of Semnan University of Medical Sciences approved this study. The Institutional Ethical Committee at Semnan University of Medical Sciences accepted all study protocols (IR.SEMUMS.REC.1400.144 ). This study was part of the general practitioner thesis of A. T. at this university.

**Funding/Support:** This study was supported by a grant from the Vice Chancellor for Research of Semnan University of Medical Sciences (grant: # A-10-116-8).

**Informed Consent:** Written informed consent was obtained from all participants before any intervention.

## References

- Shafipour V, Shafipour L, Jafari H. [The Effect of the cardiac rehabilitation program on the quality of life in patients with myocardial infarction]. *J Arak Univ Med Sci*. 2011;**5**(58):34-42. FA.
- Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2006;**113**(6):e85-151. [PubMed ID: 16407573]. <https://doi.org/10.1161/CIRCULATIONAHA.105.171600>.
- Mashaykhi NR, Sadrneya S, Chehrei A, Javaheri J, Ahmadi M. [The correlation between serum apo lipoprotein A1 and Apo lipoprotein B with coronary artery disease and its severity]. *J Arak Univ Med Sci*. 2013;**16**(6):82-9. FA.
- Parsa AFZ, Ziai H, Fallahi B. [The relationship between cardiovascular risk factors and the site and extent of coronary artery stenosis during angiography]. *Tehran Univ Med J*. 2010;**68**(3). FA.
- Lukkarinen H, Hentinen M. Treatments of coronary artery disease improve quality of life in the long term. *Nurs Res*. 2006;**55**(1):26-33. [PubMed ID: 16439926]. <https://doi.org/10.1097/00006199-200601000-00004>.
- Babapour SB, Kazemi KA. [Prevalence of coronary artery disease among the Candidate patients for cardiac valve's surgery in Tehran-Imam Khomeini Hospital (1999-2003)]. *J Arak Univ Med Sci*. 2007;**7**(3):254-8. FA.
- Abdollahi AA, Hosseini SA, Behnampour N, Salehi A. [Coronary arteries angiography findings of subjects referring to Kosar angiography center in Golestan province, Iran (2008-09)]. *J Gorgan Univ Med Sci*. 2011;**13**(1):109-14. FA.
- Smith SJ, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. *Circulation*. 2001;**103**(24):3019-41. [PubMed ID: 11413094]. <https://doi.org/10.1161/01.cir.103.24.3019>.
- Gandelman G, Bodenheimer MM. Screening coronary arteriography in the primary prevention of coronary artery disease. *Heart Dis*. 2003;**5**(5):335-44. [PubMed ID: 14503931]. <https://doi.org/10.1097/01.hdx.0000080717.15994.64>.
- Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. *Circulation*. 2012;**126**(25). <https://doi.org/10.1161/CIR.0b013e318277d6a0>.
- Shah D. Coronary artery bypass grafting (CABG): past present and future. *Gujarat Med J*. 2010;**65**:82-7.
- Alreshidan M, Albabtain M, Obied H, Alassal M, Albaradai A, Alghofaili F. Does Coronary Endarterectomy Increase Early Mortality and Morbidity Compared with Coronary Artery Bypass Surgery Alone-Single Centre Experience. *Int J Clinical Med*. 2014;**5**(5):197-205. <https://doi.org/10.4236/ijcm.2014.55033>.
- Abid AR, Farogh A, Naqshband MS, Akhtar RP, Khan JS. Hospital outcome of coronary artery bypass grafting and coronary endarterectomy. *Asian Cardiovasc Thorac Ann*. 2009;**17**(1):59-63. [PubMed ID: 19515882]. <https://doi.org/10.1177/0218492309102609>.
- Hussain I, Ghaffar A, Shahbaz A, Sami W, Muhammad A, Seher N, et al. In hospital outcome of patients undergoing coronary endarterectomy: comparison between off-pump vs on pump CABG. *J Ayub Med Coll Abbottabad*. 2008;**20**(1):31-7.
- Bailey CP, May A, Lemmon WM. Survival after coronary endarterectomy in man. *J Am Med Assoc*. 1957;**164**(6):641-6. [PubMed ID: 13428537]. <https://doi.org/10.1001/jama.1957.02980060017005>.

16. Sundt T3, Camillo CJ, Mendeloff EN, Barner HB, Gay WJ. Reappraisal of coronary endarterectomy for the treatment of diffuse coronary artery disease. *Ann Thorac Surg.* 1999;**68**(4):1272-7. [PubMed ID: 10543492]. [https://doi.org/10.1016/s0003-4975\(99\)00693-1](https://doi.org/10.1016/s0003-4975(99)00693-1).
17. Nurozler F, Kutlu T, Kucuk G, Oken C. Off-pump coronary endarterectomy in high-risk patients. *Asian Cardiovasc Thorac Ann.* 2006;**14**(3):227-30. [PubMed ID: 16714701]. <https://doi.org/10.1177/021849230601400312>.
18. Vohra HA, Kanwar R, Khan T, Dimitri WR. Early and late outcome after off-pump coronary artery bypass graft surgery with coronary endarterectomy: a single-center 10-year experience. *Ann Thorac Surg.* 2006;**81**(5):1691-6. [PubMed ID: 16631657]. <https://doi.org/10.1016/j.athoracsur.2005.12.028>.
19. Takahashi M, Gohil S, Tong B, Lento P, Filsoufi F, Reddy RC. Early and mid-term results of off-pump endarterectomy of the left anterior descending artery. *Interact Cardiovasc Thorac Surg.* 2013;**16**(3):301-5. [PubMed ID: 23190620]. [PubMed Central ID: PMC3568806]. <https://doi.org/10.1093/icvts/ivs482>.
20. Soylu E, Harling L, Ashrafian H, Athanasios T. Should we consider off-pump coronary artery bypass grafting in patients undergoing coronary endarterectomy? *Interact Cardiovasc Thorac Surg.* 2014;**19**(2):295-301. [PubMed ID: 24791957]. <https://doi.org/10.1093/icvts/ivui16>.
21. Hynes CF, Trachiotis GT. A Single Center Experience with Coronary Endarterectomy and Vein Patch Reconstruction. *World J Cardiovascular Surgery.* 2015;**5**(2):11-7. <https://doi.org/10.4236/wjcs.2015.52003>.
22. Marzban M, Karimi A, Ahmadi H, Davoodi S, Abbasi K, Movahedi N, et al. Early outcomes of double-vessel coronary endarterectomy in comparison with single-vessel coronary endarterectomy. *Texas Heart Institute Journal.* 2008;**35**(2):119.
23. Nemati MH, Astaneh B, Khosropanah S. Outcome and graft patency in coronary artery bypass grafting with coronary endarterectomy. *Korean J Thorac Cardiovasc Surg.* 2015;**48**(1):13-24. [PubMed ID: 25705593]. [PubMed Central ID: PMC4333844]. <https://doi.org/10.5090/kjtc.2015.48.1.13>.
24. Yener AÜ. The impact of coronary artery endarterectomy on mortality and morbidity during coronary artery bypass grafting. *Turkish Journal of Thoracic and Cardiovascular Surgery.* 2014;**22**(4):734-41. <https://doi.org/10.5606/tgkdc.dergisi.2014.9883>.
25. Tiruvoipati R, Loubani M, Lencioni M, Ghosh S, Jones PW, Patel RL. Coronary endarterectomy: impact on morbidity and mortality when combined with coronary artery bypass surgery. *Ann Thorac Surg.* 2005;**79**(6):1999-2003. [PubMed ID: 15919299]. <https://doi.org/10.1016/j.athoracsur.2004.12.041>.
26. Livesay JJ. Reflections on the history of coronary surgery. *Tex Heart Inst J.* 2004;**31**(3):208-9. [PubMed ID: 15562837]. [PubMed Central ID: PMC521757].
27. Sabzi F, Asadmobini A, Rezaei M. Comparing short and long term survival of patients undergoing off pump coronary artery bypass graft with and without coronary endarterectomy. *Indian Heart J.* 2017;**69**(5):646-50. [PubMed ID: 29054191]. [PubMed Central ID: PMC5650583]. <https://doi.org/10.1016/j.ihj.2017.02.008>.
28. Balaj I, Jakob H, Haddad A, Mourad F, Haneya A, Ali E, et al. Role of Antiplatelet Therapy in Patients with Severe Coronary Artery Disease Undergoing Coronary Artery Endarterectomy within Coronary Artery Bypass Surgery. *J Cardiovasc Dev Dis.* 2023;**10**(3). [PubMed ID: 36975876]. [PubMed Central ID: PMC10051999]. <https://doi.org/10.3390/jcdd10030112>.
29. Ranjan R, Adhikary D, Mandal S, Seedher A, Adhikary AB. Outcome of coronary endarterectomy with coronary artery bypass grafting in patients with diffuse coronary artery disease in Bangladesh: A retrospective cohort study. *JRSM Cardiovasc Dis.* 2017;**6**:2048004017732660. [PubMed ID: 28975025]. [PubMed Central ID: PMC5613798]. <https://doi.org/10.1177/2048004017732658>.
30. GÜVENÇ O, GÖNCÜ MT, EngİN M, ÇAYIR MÇ, ÖZYAZICIOĞLU AF. Effects of coronary endarterectomy on postoperative early results in long segment coronary artery disease. *The European Res J.* 2020;**6**(3):187-92. <https://doi.org/10.18621/eurj.486547>.
31. Rossolatos M, Papageorgiou D, Toylia G, Vasilopoulos G. Pleural effusion in patients undergoing coronary artery bypass graft and valve replacement: a population study. *Health & Res J.* 2018;**4**(3). <https://doi.org/10.12681/healthresj.19293>.
32. Ji Q, Mei Y, Wang X, Feng J, Cai J, Ding W. Risk factors for pulmonary complications following cardiac surgery with cardiopulmonary bypass. *Int J Med Sci.* 2013;**10**(11):1578-83. [PubMed ID: 24046535]. [PubMed Central ID: PMC3775118]. <https://doi.org/10.7150/ijms.6904>.
33. Labidi M, Baillot R, Dionne B, Lacasse Y, Maltais F, Boulet LP. Pleural effusions following cardiac surgery: prevalence, risk factors, and clinical features. *Chest.* 2009;**136**(6):1604-11. [PubMed ID: 19581352]. <https://doi.org/10.1378/chest.09-0689>.
34. Light RW, Rogers JT, Moyers JP, Lee YC, Rodriguez RM, Alford WJ, et al. Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery. *Am J Respir Crit Care Med.* 2002;**166**(12 Pt 1):1567-71. [PubMed ID: 12406850]. <https://doi.org/10.1164/rccm.200203-184OC>.
35. Peng MC, Hou CJ, Li JY, Hu PY, Chen CY. Prevalence of symptomatic large pleural effusions first diagnosed more than 30 days after coronary artery bypass graft surgery. *Respirol.* 2007;**12**(1):122-6. [PubMed ID: 17207037]. <https://doi.org/10.1111/j.1440-1843.2006.00972.x>.